Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tenax Therapeutics (TENX) EPS (Weighted Average and Diluted) (2023 - 2026)

Tenax Therapeutics' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.1 for Q1 2015.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 77.27% to -$0.1 in Q1 2015 year-over-year; TTM through Jan 2015 was -$0.45, a 92.27% increase, with the full-year FY2025 number at -$1.34, down 16.52% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.1 in Q1 2015 for Tenax Therapeutics, up from -$0.14 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for TENX hit a ceiling of -$0.08 in Q3 2014 and a floor of -$13.42 in Q2 2012.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$1.8 across 5 years, with a median of -$0.39 in 2012.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 11083.33% in 2012 and later surged 97.62% in 2014.
  • Tracing TENX's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.29 in 2011, then tumbled by 806.9% to -$2.63 in 2012, then skyrocketed by 52.47% to -$1.25 in 2013, then surged by 88.8% to -$0.14 in 2014, then increased by 28.57% to -$0.1 in 2015.
  • Business Quant data shows EPS (Weighted Average and Diluted) for TENX at -$0.1 in Q1 2015, -$0.14 in Q4 2014, and -$0.08 in Q3 2014.